Immutep (IMMP) vs Incannex Healthcare (IXHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immutep (IMMP) has outperformed Incannex Healthcare (IXHL) over the past year, gaining 80.8% versus a loss of 80.3%. Incannex Healthcare is the larger company by market cap ($23.3 million vs $22.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMP | IXHL |
|---|---|---|
| Share price | $3.11 | $1.86 |
| Market cap | $22.92M | $23.34M |
| 1-day change | -9.06% | +6.90% |
| YTD return | +8.74% | -82.68% |
| 1-year return | +80.81% | -80.32% |
| 5-year return | -8.53% | — |
| EPS (TTM) | $-7.30 | $-1.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | — | $-19.30M |
| 52-week high | $70.60 | $14.91 |
| 52-week low | $2.66 | $1.61 |
| Distance from 52-week high | -95.59% | -87.53% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +864.63% | +904.30% |
| Average volume | 26.07K | 91.61K |
| Shares outstanding | 7.37M | 12.55M |
| Employees | — | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed IXHL by 161.1 percentage points over the past year.
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
IMMP vs IXHL FAQ
Which is bigger, Immutep or Incannex Healthcare?
Incannex Healthcare (IXHL) is larger, with a market capitalization of $23.34M compared with $22.92M for Immutep (IMMP).
Which stock has performed better over the past year, IMMP or IXHL?
IMMP returned +80.81% over the past 12 months, compared with -80.32% for IXHL (price return, excluding dividends). Past performance does not predict future results.
Are Immutep and Incannex Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.